Pembrolizumab in combination with tocilizumab in high-risk hospitalized patients with COVID-19 (COPERNICO): A randomized proof-of-concept phase II study

Objectives: Severe COVID-19 is associated with immune dysregulation and hyperinflammation (lymphocyte exhaustion and elevated interleukin 6. Pembrolizumab (P; immune-activating anti-programmed cell death-1 antibody) plus tocilizumab (TCZ; anti- interleukin 6 receptor antibody) might interrupt the hy...

Full description

Bibliographic Details
Published in:	International Journal of Infectious Diseases
Main Authors:	Matilde Sánchez-Conde, Pilar Vizcarra, José Manuel Pérez-García, María Gion, María Pilar Martialay, Javier Taboada, Alberto Alonso-Fernández, Miguel Sampayo-Cordero, Andrea Malfettone, Isabel Tena, Sergio De La Torre, Antonio Llombart-Cussac, Javier Cortés
Format:	Article
Language:	English
Published:	Elsevier 2022-10-01
Subjects:	Pembrolizumab Tocilizumab COVID-19 SARS-CoV-2 infection
Online Access:	http://www.sciencedirect.com/science/article/pii/S1201971222004751

Similar Items

Efficacy of tocilizumab in resistant forms of Thyroid Eye Disease
by: Marković Bojan, et al.
Published: (2025-01-01)

RAPID EFFECT OF TOCILIZUMAB IN RHEUMATOID ARTHRITIS
by: E Yu Panasyuk, et al.
Published: (2011-08-01)

Comparison of Tocilizumab and Anakinra in the Treatment of COVID-19: A Single-Center Experience
by: Bengisu Pınar Acat, et al.
Published: (2022-08-01)

Subcutaneous Tocilizumab May Be Effective in Refractory Fibromyalgia Patients
by: Kuo-Tung Tang, et al.
Published: (2023-06-01)

Desensibilización exitosa con tocilizumab. Reporte de un caso
by: Luis Fernando Ramírez-Zuluaga, et al.
Published: (2018-06-01)

Tocilizumab-Induced Sweet Syndrome in a Familial Mediterranean Fever Patient: A Case Report
by: Yusuf Can Edek, et al.
Published: (2024-07-01)

PROSPECTS FOR USING TOCILIZUMAB IN SYSTEMIC SCLEROSIS
by: L. P. Ananyeva
Published: (2016-02-01)

Tocilizumab in Dengue/Flavivirus-Associated Acute Necrotizing Encephalopathy: Two Pediatric Cases
by: Lokeswari Balleda, et al.
Published: (2025-06-01)

Treating Systemic Juvenile Idiopathic Arthritis with Tocilizumab: Clinical Case
by: E. I. Alekseeva, et al.
Published: (2016-11-01)

The effect of tocilizumab administration on inflammatory markers in COVID-19 patients
by: Engy Mohamed Riyad Soliman, et al.
Published: (2024-08-01)

Pembrolizumab-induced necrotizing diaphragmatic myositis
by: David Rodríguez-Plaza, et al.
Published: (2024-06-01)

Effect of Tocilizumab Treatment on Seroconversion in Hyperinflammation Secondary to Covid 19
by: Nilgün Işıksaçan, et al.
Published: (2024-04-01)

Secondary Infection and Co-infection in COVID-19 Patients Receiving Tocilizumab
by: Çağla Erdoğan, et al.
Published: (2024-06-01)

Tocilizumab: A potent immunomodulatory agent in the treatment of COVID-19 pneumonia
by: Sameer Bansal, et al.
Published: (2021-01-01)

Effect of tocilizumab on acinetobacter baumannii lung infection in an immunosuppressed rat model
by: Demet CELEBI, et al.
Published: (2021-12-01)

Maxillary osteonecrosis linked to Pembrolizumab therapy: a case report
by: Gosselin-Rousselle Louise, et al.
Published: (2024-01-01)

Preliminary Efficacy of Tocilizumab Treatment in the Patients with COVID-19
by: Yu Chen, et al.
Published: (2021-04-01)

Predictors of Mortality in Tocilizumab-Treated Severe COVID-19
by: Konstantinos Pagkratis, et al.
Published: (2022-06-01)

THE CLINICAL AND PARACLINICAL EFFICACY OF TOCILIZUMAB IN JUVENILE IDIOPATHIC ARTHRITIS
by: Ninel REVENCO, et al.
Published: (2021-06-01)

Tocilizumab in Extracranial Giant-Cell Arteritis and Takayasu Arteritis: A Multicentric Observational Comparative Study
by: Carmen Lasa-Teja, et al.
Published: (2025-01-01)

Tocilizumab treatment in juvenile idiopathic arthritis patients: A single center experience
by: Selcan Demir, et al.
Published: (2019-04-01)

Bone-sparing effects of tocilizumab in rheumatoid arthritis: a monocentric observational study
by: Suhel Gabriele Al Khayyat, et al.
Published: (2022-11-01)

PREDICTION OF TOCILIZUMAB AND RITUXIMAB EFFECTIVENESS IN RHEUMATOID ARTHRITIS
by: Volkava M. V.
Published: (2019-11-01)

Clinical consequences of tocilizumab consumption time on COVID-19 patients
by: Shahin Keshtkar Rajabi, et al.
Published: (2024-11-01)

Tocilizumab and Renal Artery Stent–Therapeutic Strategy for Takayasu Arteritis
by: Srividhya Karunanithi, et al.
Published: (2022-07-01)

Pembrolizumab-Related Side Effects: Acute Renal Failure and Severe Neurological Toxicity
by: Gabriele Fasano, et al.
Published: (2022-01-01)

Use of Immune Modulating Agents to Regulate Hyperinflammation in Severe COVID 19: Assessment of Tocilizumab Use in Combination with Steroids
by: Somayeh Sadeghi, et al.
Published: (2024-10-01)

Dysthyroid optic neuropathy treated with tocilizumab
by: Yuerong Yan, et al.
Published: (2025-02-01)

Potential role of tocilizumab in severe gastrointestinal barrier damage after CAR T-cell therapy
by: David Beauvais, et al.
Published: (2021-04-01)

Estudio multicéntrico no intervencional en pacientes con artritis reumatoidea tratados con tocilizumab
by: F. Montoya
Published: (2015-09-01)

Estudio multicéntrico no intervencional en pacientes con artritis reumatoidea tratados con tocilizumab
by: F. Montoya, et al.
Published: (2017-09-01)

Tocilizumab (Actemra)
by: Martin Sheppard, et al.
Published: (2017-09-01)

Pembrolizumab-Induced Nasal Polyposis: The First Reported Case
by: Justin M. Hintze, et al.
Published: (2023-07-01)

Tocilizumab in Juvenile Idiopathic Arthritis Associated Uveitis, a Narrative Review
by: Claudia Iannone, et al.
Published: (2023-02-01)

Impact of tocilizumab therapy on fatigue in patients with rheumatoid arthritis
by: Anna Sergeyevna Starkova, et al.
Published: (2012-06-01)

EFFICACY AND SAFETY OF TOCILIZUMAB IN CHILDREN WITH SYSTEMIC JUVENILE ARTHRITIS IN CLINICAL PRACTICE
by: M. I. Kaleda, et al.
Published: (2015-04-01)

A single-arm study design with non-inferiority and superiority time-to-event endpoints: a tool for proof-of-concept and de-intensification strategies in breast cancer
by: Miguel Sampayo-Cordero, et al.
Published: (2023-07-01)

A spectacular effect of tocilizumab in Takayasu arteritis
by: Fatma Saïd, et al.
Published: (2024-11-01)

Diabetes Mellitus and diabetic ketoacidosis associated with pembrolizumab
by: Karla Lauš, et al.
Published: (2023-01-01)

CLINICAL CASE OF TOCILIZUMAB USE IN A PATIENT WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS
by: O. L. Lomakina, et al.
Published: (2014-01-01)